All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia.
作者信息
Thompson Meghan C, Roeker Lindsey E, Mato Anthony R
机构信息
Leukemia Service, Memorial Sloan Kettering Cancer Center.
出版信息
Haematologica. 2021 Sep 1;106(9):2300-2301. doi: 10.3324/haematol.2021.278535.
Abstract
摘要
相似文献
1
All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia.家族中的所有成员：用于治疗慢性淋巴细胞白血病的连续激酶抑制剂
Haematologica. 2021 Sep 1;106(9):2300-2301. doi: 10.3324/haematol.2021.278535.
2
Next-Generation Bruton Tyrosine Kinase Inhibitors.下一代布鲁顿酪氨酸激酶抑制剂
J Clin Oncol. 2020 Sep 1;38(25):2937-2940. doi: 10.1200/JCO.20.01594. Epub 2020 Jul 16.
3
CLL in focus: news in the treatment of chronic lymphocytic leukemia.聚焦慢性淋巴细胞白血病：慢性淋巴细胞白血病治疗的新进展
Clin Adv Hematol Oncol. 2020 Oct;18(10):627-628.
4
A new era of treatment for chronic lymphocytic leukaemia?慢性淋巴细胞白血病治疗的新时代？
Lancet Oncol. 2014 Jan;15(1):3-5. doi: 10.1016/S1470-2045(13)70558-8. Epub 2013 Dec 10.
5
B-cell receptor inhibitors in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的B细胞受体抑制剂
Clin Adv Hematol Oncol. 2011 Aug;9(8):605-6.
6
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.慢性淋巴细胞白血病淋巴细胞在依鲁替尼治疗期间布鲁顿酪氨酸激酶总蛋白水平降低。
Leukemia. 2016 Aug;30(8):1803-4. doi: 10.1038/leu.2016.129. Epub 2016 May 20.
7
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.分析慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂临床试验的挑战。
Leukemia. 2024 Jul;38(7):1469-1473. doi: 10.1038/s41375-024-02294-8. Epub 2024 Jun 1.
8
Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.依鲁替尼成功治疗慢性淋巴细胞白血病多灶性中枢神经系统受累
Turk J Haematol. 2018 May 25;35(2):147-149. doi: 10.4274/tjh.2017.0313. Epub 2018 Feb 2.
9
Ibrutinib treatment of CLL: the cancer fights back.伊布替尼治疗 CLL：癌症卷土重来。
Cancer Cell. 2014 Jul 14;26(1):11-3. doi: 10.1016/j.ccr.2014.06.023.
10
Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.依鲁替尼反应性中枢神经系统受累于慢性淋巴细胞白血病。
Blood. 2016 May 12;127(19):2356-8. doi: 10.1182/blood-2016-02-697193. Epub 2016 Mar 18.
引用本文的文献
1
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.伴有和不伴有 17p 缺失的慢性淋巴细胞白血病患者接受伊布替尼一线治疗的临床实践比较。
Haematologica. 2022 Nov 1;107(11):2630-2640. doi: 10.3324/haematol.2021.280376.
本文引用的文献
1
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.阿卡拉布替尼用于对依鲁替尼不耐受的复发/难治性慢性淋巴细胞白血病患者的II期研究。
Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500.
2
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.泊鲁替尼治疗复发或难治性 B 细胞恶性肿瘤（BRUIN）：一项 1/2 期研究。
Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5.
3
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.在不耐受 BTK 或 PI3Kδ 抑制剂治疗的 CLL 患者中，评估 umbralisib 安全性和疗效的 2 期研究。
Blood. 2021 May 20;137(20):2817-2826. doi: 10.1182/blood.2020007376.
4
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.RESONATE-2 研究 5 年随访：伊布替尼一线治疗 CLL/SLL 患者的长期疗效和安全性。
Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18.
5
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.3 项关键性研究中单药伊布替尼治疗慢性淋巴细胞白血病患者的长期安全性。
Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.
6
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.阿卡替尼单药治疗不耐受伊布替尼的慢性淋巴细胞白血病患者。
Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.
7
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.616 例美国伊布替尼治疗患者的毒性和结局：真实世界分析。
Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.
8
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.依鲁替尼治疗后进展的慢性淋巴细胞白血病的维奈托克：多中心、开放标签、2 期试验的中期分析。
Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.
9
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。
Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.
Zotero 插件